Bioserve hops on the pharmacogenomics bandwagon

The rise of pharmacogenomics has spurred Bioserve to change its business model. For years, the company specialized in analyzing genetic material for researchers. The company spent $2 million to acquire 600,000 samples of human DNA, which scientists use to discover the genetic causes of disease. And according to the Washington Post, Bioserve is offering discounts when it gets involved in the research. Now new tests for infectious diseases are being developed in India and a new deal was struck that gives researchers a tool to trace ancestral patterns in patients. The restructuring has boosted revenue 150 percent.

- check out the profile in the Washington Post

Related Articles:
New online resource for genomics. Report
Genome map completed on malaria parasite. Report
Four companies lead genome sequencing race. Report

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.